Research Topics
Species | Rolf F BarthSummaryAffiliation: The Ohio State University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Comparison of intracerebral delivery of carboplatin and photon irradiation with an optimized regimen for boron neutron capture therapy of the F98 rat gliomaRolf F Barth
Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
Appl Radiat Isot 69:1813-6. 2011..However, a significant problem that must be solved for both BNCT and this new chemoradiotherapeutic approach is how to improve drug uptake and microdistribution within the tumor...
Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancerRolf F Barth
Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, OH, 43210, USA
Radiat Oncol 7:146. 2012..Finally, we will summarize the critical issues that must be addressed if BNCT is to become a more widely established clinical modality for the treatment of those malignancies for which there currently are no good treatment options...- Boron neutron capture therapy at the crossroads: challenges and opportunitiesRolf F Barth
Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA
Appl Radiat Isot 67:S3-6. 2009..These challenges notwithstanding, BNCT can fill an important niche for those malignancies, whether primary or recurrent, for which there is currently no effective therapy... - Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomasRolf F Barth
Department of Pathology, The Ohio State University, 165 Hamilton Hall, Columbus, OH 43210, USA
J Neurooncol 94:299-312. 2009..It is essential to recognize the limitations of each of the models that have been described, and depending upon the nature of the study to be conducted, it is important that the appropriate model be selected... - Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumorsRolf F Barth
Department of Pathology, Division of Biostatistics, Ohio State University, Columbus, OH 43210, USA
Proc Natl Acad Sci U S A 105:17493-7. 2008..Further studies are planned to design and synthesize 3CTAs with enhanced chemical and biological properties, and increased therapeutic efficacy... - Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumorsWeilian Yang
Department of Pathology, The Ohio State University, 165 Hamilton Hall, Columbus, OH 43210, USA
J Neurooncol 95:355-65. 2009..006), following i.c CED of BD-EGF compared to i.t injection, and that the survival data were equivalent to those previously reported by us using the boronated anti-human-EGF mAb, C225 (cetuximab)... 
Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomasWeilian Yang
Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA
Appl Radiat Isot 61:981-5. 2004..These data show that CED improved the radiobiological effectiveness of BD-EGF and lay the groundwork for future studies using combinations of boron delivery agents for NCT of EGFR(+) gliomas...- Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4Weilian Yang
Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, 43210, USA
Clin Cancer Res 12:3792-802. 2006.... - Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agentRolf F Barth
Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA
Appl Radiat Isot 61:899-903. 2004..These data are the first to demonstrate the efficacy of a boronated MoAb for BNCT of an intracerebral (i.c.) glioma and are paradigmatic for future studies using a combination of boronated MoAbs and low molecular weight delivery agents... - Combination of boron neutron capture therapy and external beam radiotherapy for brain tumorsRolf F Barth
Department of Pathology, Ohio State University, Columbus, OH 43210, USA
Int J Radiat Oncol Biol Phys 58:267-77. 2004..Two brain tumor models were used, the F98 glioma as a model for primary brain tumors and the MRA 27 human melanoma as a model for metastatic brain tumors... - Synthesis and biological evaluation of neutral and zwitterionic 3-carboranyl thymidine analogues for boron neutron capture therapyYoungjoo Byun
Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
J Med Chem 48:1188-98. 2005..2004, 64, 6280-6286 and 6287-6295). To complete previous structure-activity relationship (SAR) studies, 3-[(closo-o-carboranyl)methyl]thymidine (4) was also synthesized and evaluated... - Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapyGong Wu
Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, Ohio 43210, USA
Anticancer Agents Med Chem 6:167-84. 2006..Finally, we will conclude with a discussion relating to issues that must be addressed if these HMW agents are to be used clinically... - Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximabGong Wu
Department of Pathology, The Ohio State University, Columbus 43210, USA
Clin Cancer Res 13:1260-8. 2007.... - Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumorsWeilian Yang
Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA
J Neurooncol 101:379-90. 2011.... - Boronated thymidine analogues for boron neutron capture therapyB T S Thirumamagal
College of Pharmacy, The Ohio State University, Columbus, Ohio 43120, USA
Nucleosides Nucleotides Nucleic Acids 25:861-6. 2006..The synthesis of these potential boron neutron capture therapy (BNCT) agents and their preliminary biological evaluation is described... - Preparation and biological evaluation of 10B-enriched 3-[5-{2-(2,3-dihydroxyprop-1-yl)-o-carboran-1-yl}pentan-1-yl]thymidine (N5-2OH), a new boron delivery agent for boron neutron capture therapy of brain tumorsYoungjoo Byun
Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, OH, USA
J Med Chem 49:5513-23. 2006.... - Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT)B T S Thirumamagal
Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, 43210, USA
Bioconjug Chem 17:1141-50. 2006.... - Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4Weilian Yang
Department of Pathology, The Ohio State University, Columbus, Ohio 43210, USA
Clin Cancer Res 11:341-50. 2005..CONCLUSIONS: Based on these data, we have concluded that the F98(npEGFRvIII) glioma should be a valuable animal model for therapy studies focusing on molecular targeting of EGFRvIII by receptor specific mAbs... - Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumorsRolf F Barth
Department of Pathology, The Ohio State University, Columbus, Ohio 43210, USA
Cancer Res 64:6287-95. 2004..Based on these favorable in vitro and in vivo data, neutron capture therapy studies will be initiated using N5-2OH in combination with two non-cell cycle dependent boron delivery agents, boronophenylalanine and sodium borocaptate... - Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapySupriya Shukla
College of Pharmacy, Department of Pathology, The Ohio State University, Columbus, Ohio 43210, USA
Bioconjug Chem 14:158-67. 2003..0% ID/g tumor), but also high hepatic (38.8% ID/g) and renal (62.8% ID/g) uptake, indicating that attachment of a second PEG unit and/or folic acid may adversely affect the pharmacodynamics of this conjugate... - Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapyGong Wu
Department of Pathology and College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
Bioconjug Chem 15:185-94. 2004..t. injection, thereby demonstrating specific molecular targeting of EGFR. Based on these data, BNCT studies will be initiated in F98EGFR glioma bearing rats to evaluate C225-G5-B1100 for the treatment of intracerebral brain tumors... - Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapyStacy M Stephenson
Division of Pharmaceutics, Ohio State University, Columbus, OH 43210, USA
Anticancer Res 23:3341-5. 2003..CONCLUSION: Boron delivery via FR-targeted liposomes is feasible and potentially can improve tumor uptake compared to non-targeted liposomes, and may improve cellular and subcellular localization... - Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomasWeilian Yang
Department of Pathology, The Ohio State University, Columbus, Ohio 43210, USA
Cancer Res 62:6552-8. 2002..t. injection and 12.3%ID/g in F98(WT) gliomas. On the basis of these observations, we have concluded that CED is more effective than i.t. injection as a way to deliver boronated EGF to EGFR (+) gliomas for boron neutron capture therapy... - Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodiesWeilian Yang
Department of Pathology, The Ohio State University, Columbus, Ohio 43210, USA
Clin Cancer Res 14:883-91. 2008.... - 3-Carboranyl thymidine analogues (3CTAs) and other boronated nucleosides for boron neutron capture therapyYoungjoo Byun
College of Pharmacy, The Ohio State University, Columbus, OH, USA
Anticancer Agents Med Chem 6:127-44. 2006..This review will analyze design strategies applied for the synthesis of boron-containing nucleosides in general and in particular reference to 3CTAs. Results of biological studies with these molecules will be discussed... - Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugatesGong Wu
Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, 43210, USA
Mol Cancer Ther 5:52-9. 2006..Our results, which are both positive and negative, show that specific molecular targeting is but one of several requirements that must be fulfilled if an antibody-drug bioconjugate will be therapeutically useful... - Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomasRolf F Barth
Department of Pathology, The Ohio State University, 1645 Neil Avenue, Columbus, OH 43210, USA
Cancer Res 62:3159-66. 2002.... - Folate receptor-mediated liposomal delivery of a lipophilic boron agent to tumor cells in vitro for neutron capture therapyJennifer J Sudimack
College of Pharmacy, The Ohio State University, Columbus 43210, USA
Pharm Res 19:1502-8. 2002..Such liposomes warrant further investigations for use in neutron capture therapy... - Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFRXiaogang Pan
Division of Pharmaceutics, College of Pharmacy, NSF Nanoscale Science and Engineering Center NSEC, Center for Affordable Nanoengineering of Polymeric Biomedical Devices CANPBD, The Ohio State University, Columbus, Ohio 43210, USA
Bioconjug Chem 18:101-8. 2007..On the basis of these observations, we have concluded that cholesterol can serve as an effective anchor for MAb in liposomes, and cetuximab-ILs are potentially useful delivery vehicles for BNCT of gliomas... - Pharmacokinetics of sodium borocaptate: a critical assessment of dosing paradigms for boron neutron capture therapyChristopher R Gibson
College of Pharmacy, Division of Pharmaceutics, The Ohio State University, Columbus, OH, USA
J Neurooncol 62:157-69. 2003..v. infusion. The results from our study are confirmatory of those previously reported by others when blood sampling has been carried out for a sufficient period of time to adequately characterize the pharmacokinetics... - Rat brain tumor models to assess the efficacy of boron neutron capture therapy: a critical evaluationRolf F Barth
Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
J Neurooncol 62:61-74. 2003..Be that as it may, rat brain tumor models already have made a significant contribution to the design of clinical BNCT protocols, and should continue to do so in the future... - Preparation, biodistribution and neurotoxicity of liposomal cisplatin following convection enhanced delivery in normal and F98 glioma bearing ratsTianyao Huo
Department of Pathology, The Ohio State University, Columbus, Ohio, United States of America
PLoS ONE 7:e48752. 2012..c. by CED for the treatment of brain tumors and that a formulation that may be safe when given systemically may be highly neurotoxic when administered directly into the brain... - Synthesis, biological evaluation, and radioiodination of halogenated closo-carboranylthymidine analoguesRohit Tiwari
Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, 500 West 12th Avenue, Columbus, Ohio 43210, USA
Inorg Chem 51:629-39. 2012..0% to 29.6% relative to that of thymidine, the endogenous hTK1 substrate. The in vitro uptake of N5, N5-(127)I, and N5-(79/81)Br in L929 TK1(+) cells was 2.0, 1.8, and 1.4 times greater than that in L929 TK1(-) cells... - Lipid-coated nano-calcium-phosphate (LNCP) for gene deliveryChenguang Zhou
Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
Int J Pharm 392:201-8. 2010.... - Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphomaSameek Roychowdhury
Department of Molecular Virology, Immunology, Medical Genetics, The Ohio State University, Columbus, Ohio, 43210, USA
Cancer Res 63:965-71. 2003..These results suggest that antiviral therapies can be effectively explored in vivo using a preclinical animal model of human EBV(+) PCNSL with subsequent translation to patients with EBV(+) PCNSL... - Boron neutron capture therapy of cancer: current status and future prospectsRolf F Barth
Department of Pathology, The Ohio State University, Columbus, Ohio 43210, USA
Clin Cancer Res 11:3987-4002. 2005..If these issues are adequately addressed, then BNCT could move forward as a treatment modality... - Neutron capture therapy of intracerebral melanoma: enhanced survival and cure after blood-brain barrier opening to improve delivery of boronophenylalanineRolf F Barth
Department of Pathology, Ohio State University, Columbus, OH 43210, USA
Int J Radiat Oncol Biol Phys 52:858-68. 2002.... - High resolution ultra high field magnetic resonance imaging of glioma microvascularity and hypoxia using ultra-small particles of iron oxideGregory A Christoforidis
Department of Radiology, The Ohio State University Medical Center, Columbus, OH 43210, USA
Invest Radiol 44:375-83. 2009..In an effort to explain differences in visualization of microvascularity before and after USPIO administration, hypoxia and vessel diameters were assessed on corresponding histopathologic sections... - Boron-containing folate receptor-targeted liposomes as potential delivery agents for neutron capture therapyXing Q Pan
College of Pharmacy and Department of Pathology, The Ohio State University, Columbus 43210, USA
Bioconjug Chem 13:435-42. 2002..Our findings suggest that further evaluation of FR-targeted liposomes is warranted to assess their potential as boron carriers for neutron capture therapy... - Unique in vitro and in vivo thrombopoietic activities of ingenol 3,20 dibenzoate, a Ca(++)-independent protein kinase C isoform agonistFrederick K Racke
Department of Pathology, The Ohio State University School of Medicine, Columbus, Ohio, United States of America
PLoS ONE 7:e51059. 2012..Our data demonstrate that novel PKC isoform agonists such as IDB may represent a unique therapeutic strategy for accelerating the recovery of platelet counts following severe marrow injury... - Electrospray ionization mass spectrometry coupled to reversed-phase ion-pair high-performance liquid chromatography for quantitation of sodium borocaptate and application to pharmacokinetic analysisChristopher R Gibson
College of Pharmacy, Department of Pathology, The Ohio State University, Columbus 43210, USA
Anal Chem 74:2394-9. 2002..The mean total body plasma clearance was 95.7 +/- 30.8 m/min and the harmonic mean terminal half-life was 3.6 h... - Boron neutron capture therapy for the treatment of glioblastomas and extracranial tumours: as effective, more effective or less effective than photon irradiation?Rolf F Barth
Department of Pathology, The Ohio State University, OH, USA
Radiother Oncol 82:119-22. 2007 - A critical assessment of boron neutron capture therapy: an overviewRolf F Barth
Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
J Neurooncol 62:1-5. 2003..Clinical studies have demonstrated the safety of BNCT. The next challenge is an unequivocal demonstration of therapeutic efficacy in one or more of the clinical trails that either are in progress or are planned over the next few years...